Ana Carolina da Cruz, Simon Sawhney, Thomas Alexander Gerds, Anders Munch, Robert R Quinn, Emir Sevinc, Mitchell Rath, Ngan N Lam, Paul E Ronksley, Tyrone G Harrison, Matthew T James, Gregory L Hundemer, Neesh Pannu, Ping Liu, Na Li, Pietro Ravani
{"title":"Applicability of Prediction Models: Aligning Models with Clinical Use.","authors":"Ana Carolina da Cruz, Simon Sawhney, Thomas Alexander Gerds, Anders Munch, Robert R Quinn, Emir Sevinc, Mitchell Rath, Ngan N Lam, Paul E Ronksley, Tyrone G Harrison, Matthew T James, Gregory L Hundemer, Neesh Pannu, Ping Liu, Na Li, Pietro Ravani","doi":"10.1016/j.kint.2026.10.017","DOIUrl":"https://doi.org/10.1016/j.kint.2026.10.017","url":null,"abstract":"<p><p>Doctors increasingly rely on models that predict a patient's risk of future health problems. These models only work well when the patients they were built on resemble the patients being treated now, in illness type, care setting, and stage of disease. This is easy to see when the mismatch is obvious: a model built on hospital patients may not suit those seen in a family doctor's office. The same problem is harder to appreciate when it comes from where a patient sits on a chronic illness journey. Using severe chronic kidney disease as an example, this review shows that a model built from patients who have recently progressed to this more severe stage works better for patients at that same point, while a model built from patients who have lived with the disease for years works better for those further along. This review offers practical steps to keep predictions aligned with the patients they serve.</p>","PeriodicalId":17801,"journal":{"name":"Kidney international","volume":" ","pages":""},"PeriodicalIF":21.8,"publicationDate":"2026-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149407600","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Clara J Fischman, Jarcy Zee, Yizhe Xu, Yuxin Zhao, Adam Bress, Blessing Ofori-Atta, Rachel Shulman, Jaden Crump, Daniel J Rader, Jordana B Cohen
{"title":"Pooled cohort analysis of renin-angiotensin system inhibition and the risk of kidney outcomes in APOL1-mediated chronic kidney disease in the CRIC and SPRINT studies.","authors":"Clara J Fischman, Jarcy Zee, Yizhe Xu, Yuxin Zhao, Adam Bress, Blessing Ofori-Atta, Rachel Shulman, Jaden Crump, Daniel J Rader, Jordana B Cohen","doi":"10.1016/j.kint.2026.10.023","DOIUrl":"https://doi.org/10.1016/j.kint.2026.10.023","url":null,"abstract":"<p><strong>Introduction: </strong>Apolipoprotein L1 (APOL1) variants are common in individuals of African descent and increase risk of chronic kidney disease (CKD). Renin-angiotensin system inhibitors (RASis) are a mainstay of therapy for hypertension and proteinuric CKD but were not historically recommended as first-line anti-hypertensive therapy in Black individuals. Here, we evaluated RASis versus other antihypertensive therapy on kidney outcomes in Black individuals by APOL1 genotype.</p><p><strong>Methods: </strong>We included Black participants with APOL1 genotyping on first-line anti-hypertensive therapy from the Chronic Renal Insufficiency Cohort (CRIC) and Systolic Blood Pressure Intervention Trial (SPRINT). We evaluated whether the impact of RASi-prescription on kidney outcomes was modified by APOL1 risk allele number or baseline albuminuria, using Cox models with inverse probability of treatment weighting and marginal structural models.</p><p><strong>Results: </strong>A total of 3418 participants (62% from SPRINT), 40%, 44% and 16% carrying zero, one and two APOL1 risk alleles, respectively, were included. RASi-use compared to other first-line antihypertensive therapy was associated with a comparably lower risk of the kidney outcome in individuals with zero (hazard ratio (HR) 0.62 [95% confidence interval (CI) 0.44-0.87]), one (HR 0.68 [95% CI 0.49-0.94]) or two risk alleles (HR 0.59 [95% CI 0.40-0.86]). This benefit was driven by albuminuric participants, but estimates were similarly low for RASi-use compared to other antihypertensive therapy in albuminuric (HR 0.62, 95% CI [0.41-0.93]) and non-albuminuric (HR 0.37, 95% CI [0.13-1.08]) participants with two APOL1 risk alleles, although the estimate was imprecise in non-albuminuric participants.</p><p><strong>Conclusions: </strong>RASi-based therapy, addressed as a time-updated pooled treatment, provided similar benefit across APOL1 genotypes, driven by albuminuric participants. Among individuals with two APOL1 risk alleles, outcomes were similar regardless of baseline albuminuria. However, further studies are needed due to small sample sizes and the inability of statistical methods to capture clinical variables that may have affected prescription changes.</p>","PeriodicalId":17801,"journal":{"name":"Kidney international","volume":" ","pages":""},"PeriodicalIF":21.8,"publicationDate":"2026-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149407602","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Metabolic Unloading: How SGLT2i Recalibrate Cell Energetics to Slow CKD Progression.","authors":"Victor Martinez Leon, Sandeep Aggarwal","doi":"10.1016/j.kint.2026.10.018","DOIUrl":"https://doi.org/10.1016/j.kint.2026.10.018","url":null,"abstract":"<p><p>Kidney outcome trials demonstrate that sodium-glucose cotransporter 2 inhibitors consistently slow chronic kidney disease progression; however, the underlying mechanisms remain incompletely defined, as benefits extend beyond glycemic control and hemodynamic effects across diabetic and non-diabetic chronic kidney disease. This review advances a unifying framework in which metabolic unloading of the proximal tubule contributes to renoprotection. The metabolic burden of solute reabsorption places the proximal tubule at the center of renal energetics, predisposing it to hypoxia, mitochondrial stress, and maladaptive injury responses. We synthesize evidence that these agents reduce adenosine triphosphate-dependent transport workload, oxygen consumption and may also reduce megalin-dependent endocytosis, with downstream effects on mitochondrial efficiency, redox balance, and autophagy/mitophagy supported by emerging preclinical data. By mitigating energetic stress, these agents divert tubular cell fate away from maladaptive hypertrophy and fibrosis toward adaptive repair. This framework integrates spatial cortex-medulla vulnerability, reconciles early hemodynamic changes with durable slowing of estimated glomerular filtration rate decline, and explores disease-agnostic benefit. We discuss translational implications including early initiation, identification of high workload phenotypes (hyperfiltration, recovery after acute kidney injury), and deployment of energetics associated biomarkers such as ketones, oxidative stress profiles, and estimated glomerular filtration rate slope. This review positions cellular energetics as an important upstream constraint shaping kidney disease progression, offering a foundation for nephroprotective strategies.</p>","PeriodicalId":17801,"journal":{"name":"Kidney international","volume":" ","pages":""},"PeriodicalIF":21.8,"publicationDate":"2026-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149394671","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Thomas Robert, Laure Raymond, Xavier Vanhoye, Fanny Ponce, Laurent Mesnard
{"title":"Systematic overestimation using in silico-driven curation in a population database caused reevaluation of the genetic prevalence of Alport Syndrome.","authors":"Thomas Robert, Laure Raymond, Xavier Vanhoye, Fanny Ponce, Laurent Mesnard","doi":"10.1016/j.kint.2026.10.012","DOIUrl":"https://doi.org/10.1016/j.kint.2026.10.012","url":null,"abstract":"<p><strong>Introduction: </strong>A landmark study by Gibson and coworkers in 2021 estimated that one in 106 individuals carry a predicted pathogenic COL4A3 or COL4A4 variant, suggesting autosomal dominant Alport syndrome is massively underdiagnosed. However, pathogenicity of all triple-helical Glycine substitutions was inferred using in silico tools, which may overestimate prevalence.</p><p><strong>Methods: </strong>COL4A3, COL4A4, and COL4A5 variants were extracted from population database gnomADv4.1.1 (about 800,000 individuals, including UK Biobank) and from a clinical exome cohort of 29,055 patients (Eurofins Biomnis), stratified into a kidney disease group (KIDNEY) of 8663 individuals and 20,392 individuals of a non-kidney control group (NON-KIDNEY). Three curation strategies were compared: a ClinVar-dependent model, an in silico-driven model adapted from Gibson, and an Expert Strategy combining stringent allele frequency thresholds, high-confidence loss-of-function filtering, and with ClinVar validation for missense variants. Estimates were validated against the control group and replicated in the non-UKB Biobank subset.</p><p><strong>Results: </strong>Applied to gnomADv4.1.1, the Gibson methodology yielded one in 221, a 52% reduction from the original one in 106 (gnomADv2). The Expert Strategy estimated one in 283, validated in the NON-KIDNEY group (one in 295; concordance ratio 0.96), whereas Gibson inflated the control rate by 91% (one in 154 vs. one in 295). Glycine substitutions (COL4A3 p.Gly1277Ser odds ratio 0.95; COL4A4 p.Gly999Glu odds ratio 1.01) were misclassified by all in silico tools. Expert Strategy variants were found in one in 44 KIDNEY patients (odds ratio 6.76). Enrichment was unchanged by high-confidence loss-of-function restriction.</p><p><strong>Conclusions: </strong>Autosomal dominant Alport syndrome affects one in 283 individuals, one to two orders of magnitude above classical clinical estimates (one in 5,000 to one in 53,000), confirming underdiagnosis, but substantially lower than the Gibson estimate. These findings argue for downgrading the PM2 rarity criterion in collagenopathies. Systematic COL4A3/COL4A4 screening in chronic kidney disease is justified by a diagnostic yield of one in 44.</p>","PeriodicalId":17801,"journal":{"name":"Kidney international","volume":" ","pages":""},"PeriodicalIF":21.8,"publicationDate":"2026-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149342655","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
You Zuo, Veerle A Lantinga, Elizabeth Orozco-García, Baran Ogurlu, Cyril Moers
{"title":"Advances in assessing donor organ quality and perioperative risk for kidney transplantation.","authors":"You Zuo, Veerle A Lantinga, Elizabeth Orozco-García, Baran Ogurlu, Cyril Moers","doi":"10.1016/j.kint.2026.07.040","DOIUrl":"https://doi.org/10.1016/j.kint.2026.07.040","url":null,"abstract":"<p><p>Kidney transplantation faces persistent challenges in accurately evaluating donor organ quality and predicting long-term outcomes, with traditional assessment methods demonstrating limited predictive capacity. The increasing utilization of marginal-quality donor organs has intensified the need for sophisticated evaluation strategies. Machine perfusion technology has transformed organ preservation from mere static storage to a dynamic platform potentially enabling real-time monitoring, assessment, and interventions during the preservation period. Molecular profiling technologies such as genomics, transcriptomics, proteomics, and metabolomics could provide refined biomarkers for donor kidney assessment across several phases of kidney transplantation. The first window arises during donor evaluation. Techniques such as high-resolution molecular typing, genetic profiling, epigenomic markers, and artificial intelligence-enhanced imaging provide additional information compared to traditional scoring systems. During organ preservation, a second window emerges, allowing additional, isolated assessment of the organ after procurement but before transplantation. Machine perfusion systems enable sampling of perfusate and tissue for multi-omics analysis to characterize injury or function, although most candidate biomarkers remain at the discovery or early validation stage. After transplantation, donor-derived cell-free deoxyribonucleic acid, urinary chemokines, and advanced imaging modalities offer non-invasive early detection of graft injury. Clinical translation of these new techniques faces substantial challenges: most studies are single-center and have small sample sizes, assay standardization remains incomplete, and evidence linking biomarker-guided decisions to improved long-term graft survival is lacking. Machine learning may enhance risk stratification but remains largely unvalidated in prospective trials. Future progress requires a shift from short-term endpoint prediction to long-term outcome validation through multicenter studies, standardized protocols, and equitable implementation strategies.</p>","PeriodicalId":17801,"journal":{"name":"Kidney international","volume":" ","pages":""},"PeriodicalIF":21.8,"publicationDate":"2026-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149342700","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Dong-Yuan Chang, Zeguo Sun, Xuezhu Li, Wei Cai, Weijia Zhang, Vivette D D'Agati, David Salant, John C He, Jia Fu, Kyung Lee
{"title":"Ontogenically distinct macrophages occupy discrete kidney niches and contribute to monocyte recruitment in experimental crescentic glomerulonephritis.","authors":"Dong-Yuan Chang, Zeguo Sun, Xuezhu Li, Wei Cai, Weijia Zhang, Vivette D D'Agati, David Salant, John C He, Jia Fu, Kyung Lee","doi":"10.1016/j.kint.2026.10.011","DOIUrl":"10.1016/j.kint.2026.10.011","url":null,"abstract":"<p><strong>Introduction: </strong>Crescentic glomerulonephritis (cGN) is characterized by aggressive immune-mediated glomerular injury with prominent macrophage accumulation that correlates with disease severity. However, the distinct contributions of kidney-resident macrophages (KRMs) of different ontogenies remain poorly defined.</p><p><strong>Methods: </strong>To explore this, we used single-cell RNA sequencing (scRNA-seq), reporter-based bone marrow chimeras, timed clodronate liposome treatment, and chemokine blockade to define the spatiotemporal dynamics and functional roles of macrophage populations in nephrotoxic serum nephritis (NTSN), a model of cGN.</p><p><strong>Results: </strong>scRNA-seq of total kidney and CD45<sup>+</sup> immune cells revealed that proliferating macrophages and infiltrating monocytes expanded sharply by day five and declined by day ten, indicating that local proliferation, in addition to monocyte recruitment, contributes substantially to early macrophage accumulation in NTSN. Two major KRM subpopulations were distinguished by high Ccr2 or Mrc1 expression, consistent with bone marrow and embryonically seeded, self-renewing KRM population, respectively. In Cx3cr1-GFP recipient mice reconstituted with Ccr2-RFP<sup>+</sup> donor bone marrow, embryonic-derived GFP<sup>+</sup> KRMs were enriched in the outer medulla and corticomedullary region, whereas donor-derived RFP<sup>+</sup> monocytes/macrophages preferentially accumulated in the cortex, including within and around the inflamed glomeruli. A timed clodronate liposome regimen that preferentially reduced recipient-retained GFP<sup>+</sup> KRMs decreased the cortical accumulation of RFP<sup>+</sup> cells, albuminuria, and histologic kidney injury in NTSN mice. Cell-cell communication analysis identified macrophage-associated CCL12 expression, a murine ortholog of human CCL2, as a candidate mediator of cortical CCR2<sup>+</sup> monocyte recruitment. CCL12 neutralization reduced cortical monocyte accumulation and ameliorated kidney damage in NTSN mice.</p><p><strong>Conclusions: </strong>These findings indicate that ontogenically distinct and spatially segregated macrophage populations cooperate during early cGN and support further investigation of the CCR2 axis as a therapeutic target for macrophage-mediated kidney injury in cGN.</p>","PeriodicalId":17801,"journal":{"name":"Kidney international","volume":" ","pages":""},"PeriodicalIF":21.8,"publicationDate":"2026-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149342654","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Gerald Ponath, Claudius Speer, Daniela Kim, Anita Schmitt, Mehmet Kaan Özdemir, Volker Daniel, Christian Kleist, Peter Terness, Gerhard Opelz, Hanns-Martin Lorenz, Michael Schmitt, Julia Weinmann-Menke, Martin Zeier, Christian Morath, Matthias Schaier
{"title":"Modified immune cell therapy targets kidney-resident tertiary lymphoid structures and ameliorates murine lupus nephritis.","authors":"Gerald Ponath, Claudius Speer, Daniela Kim, Anita Schmitt, Mehmet Kaan Özdemir, Volker Daniel, Christian Kleist, Peter Terness, Gerhard Opelz, Hanns-Martin Lorenz, Michael Schmitt, Julia Weinmann-Menke, Martin Zeier, Christian Morath, Matthias Schaier","doi":"10.1016/j.kint.2026.10.013","DOIUrl":"10.1016/j.kint.2026.10.013","url":null,"abstract":"<p><strong>Introduction: </strong>Modified immune cells (MIC), i.e. mononuclear cells challenged with mitomycin C can induce immunotolerance. MIC treatment has been successful in several animal models of autoimmunity and in clinical trials after solid organ transplantation, but the mechanism for reduced inflammation is not fully understood.</p><p><strong>Methods: </strong>To investigate the efficacy of MIC therapy in lupus nephritis, splenocytes from syngeneic NZB/W F1 (BWF1) donor mice were incubated with mitomycin C, and then into BWF1 recipients at 25 weeks of age. Animals were followed for another five weeks to assess disease progression by histological, flow cytometric, and serological parameters. An in vitro phagocytosis assay was conducted to determine the clearance of MIC from 25 patients with lupus and from matched healthy individuals by autologous macrophages.</p><p><strong>Results: </strong>In BWF1 mice, MIC therapy reduced the clinical burden of lupus nephritis disease progression with lower protein excretion and lower serum creatinine levels in the standard-dose compared to the control group. High-dose MIC therapy during active diseases showed no additional benefit. More than 86% of animals had dense lymphocytic aggregates close to the kidney pelvis. These tertiary lymphoid structures differed between MIC-treated animals and controls, with a loss of organization, loss of separation of B-cell and T-cell areas and disintegration of germinal centers after MIC treatment. In the peripheral blood, MIC-treated animals had higher numbers of CD19<sup>+</sup>CD5<sup>+</sup>CD1d<sup>high</sup> regulatory-like B lymphocytes. Although MIC treatment was beneficial, higher dosing offered no additional clinical benefit in mice. Macrophages from the patients with lupus efficiently cleared MIC in vitro, ruling out defective clearance as a limiting factor.</p><p><strong>Conclusions: </strong>Our clinically applicable cell therapy approach has the potential to control lupus nephritis by specifically dampening deleterious autoimmune responses.</p>","PeriodicalId":17801,"journal":{"name":"Kidney international","volume":" ","pages":""},"PeriodicalIF":21.8,"publicationDate":"2026-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149342653","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Silke R Brix, Martina Uzzo, Andreas Kronbichler, Beatriz Sanchez-Alamo, Aglaia Chalkia, Balazs Odler, Alexandre Karras, Aladdin J Mohammad, Irmgard Neumann, Oliver Flossmann, Ioannis Parodis, Wladimir M Szpirt, Annette Bruchfeld, Augusto Vaglio, Kerstin Westman, David Jayne, Ingeborg Bajema
{"title":"Kidney Endpoints in ANCA-Associated Vasculitis - Position Report from the European Vasculitis Society Focus Group Meetings.","authors":"Silke R Brix, Martina Uzzo, Andreas Kronbichler, Beatriz Sanchez-Alamo, Aglaia Chalkia, Balazs Odler, Alexandre Karras, Aladdin J Mohammad, Irmgard Neumann, Oliver Flossmann, Ioannis Parodis, Wladimir M Szpirt, Annette Bruchfeld, Augusto Vaglio, Kerstin Westman, David Jayne, Ingeborg Bajema","doi":"10.1016/j.kint.2026.10.010","DOIUrl":"https://doi.org/10.1016/j.kint.2026.10.010","url":null,"abstract":"<p><p>Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV) often affect the kidneys, driving morbidity and mortality in AAV. Clinical trials have investigated kidney outcomes using a variety of definitions. The standardization of kidney disease response criteria in AAV remains an unmet need, with an urgency to define kidney endpoints for daily clinical practice and new drug development to optimize patient management. A European Vasculitis Society (EUVAS) Focus Group was formed to review the literature and discuss the wide range of definitions used. The group involved nephrologists, pathologists and rheumatologists who met four times over a time frame of two years with the objective of formulating a consensus proposal for standardized kidney endpoint definitions for AAV. The group investigated the terminology and outcome relations of active kidney disease, treatment response and refractory kidney disease, remission and relapse, kidney function recovery and kidney failure requiring kidney replacement therapy. The group reviewed and discussed measurable parameters used for the assessments, such as kidney biopsy, hematuria and proteinuria, serum creatinine and estimated glomerular filtration rate and novel biomarkers. Here, we report on the current variability in terminology, present an expert proposal for kidney endpoints with a research agenda and outline the future strategy for a Delphi consensus.</p>","PeriodicalId":17801,"journal":{"name":"Kidney international","volume":" ","pages":""},"PeriodicalIF":21.8,"publicationDate":"2026-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149322598","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Suzanne Bezstarosti, Aleksandar Senev, Anna B Morris, Sebastiaan Heidt
{"title":"Alloimmune risk stratification for kidney transplantation.","authors":"Suzanne Bezstarosti, Aleksandar Senev, Anna B Morris, Sebastiaan Heidt","doi":"10.1016/j.kint.2026.07.039","DOIUrl":"https://doi.org/10.1016/j.kint.2026.07.039","url":null,"abstract":"<p><p>Alloreactivity after kidney transplantation occurs via both memory responses resulting from prior sensitization and de novo responses that develop due to donor-recipient disparity for the human leukocyte antigen (HLA) complex. HLA compatibility (absence of HLA-DSA) and the degree of HLA matching inform on the likelihood of allorecognition that can cause allograft rejection and allograft loss, and are therefore the two pillars of alloimmune risk assessment. Over the past decades, the detection of anti-HLA antibodies has become more sensitive and specific through single antigen bead testing, and advances in HLA typing from serology to DNA level have been instrumental for more detailed analysis of HLA compatibility. Nonetheless, alloimmune risk stratification using antigen-level HLA data has limited ability to accurately predict the risk of de novo anti-HLA responses and long-term graft outcome after transplantation, especially on the individual patient level. Aiming to improve long-term outcomes by improving HLA matching, HLA molecular mismatch algorithms have been developed. In this review, we discuss the advances, clinical evidence, limitations and clinical implementability of HLA molecular mismatch analysis to increase precision in alloimmune risk stratification in kidney transplantation. In addition, we provide an overview of the different molecular mismatch tools and their potential application in personalized medicine, such as organ allocation, criteria for donor acceptance and individualized immunosuppression.</p>","PeriodicalId":17801,"journal":{"name":"Kidney international","volume":" ","pages":""},"PeriodicalIF":21.8,"publicationDate":"2026-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149298486","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}